Menu Search
Equities

NRX Pharmaceuticals Inc

B1Q:BER

NRX Pharmaceuticals Inc

Actions
  • Price (EUR)4.36
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+57.97%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 19:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

  • Revenue in USD (TTM)0.00
  • Net income in USD-20.39m
  • Incorporated2017
  • Employees2.00
  • Location
    NRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
  • Phone+1 (484) 254-6134
  • Fax+1 (302) 575-1642
  • Websitehttps://www.nrxpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.